Proffice and AstraZeneca Plan to Extend Their Relationship

Regulatory News:

Proffice (STO:PROEB) has been appointed Managed Service Provider by AstraZeneca and the parties intend to enter into a Managed Service Provider agreement for a period of five years with effect from spring 2013.

The partnership described above would also entail that Proffice would continue to be one of the primary suppliers of staffing services to AstraZeneca.

AstraZeneca has also appointed Proffice to handle its holiday/intern workers in 2013, which is in addition to the appointment as Managed Service Provider, and the parties have entered into negotiations in order to formalize such assignment.

"We are extremely proud and pleased with the confidence AstraZeneca has shown in us in this strategic cooperation," says Lars Kry, CEO, Proffice AB.

Proffice is one of the Nordic region's largest specialists in staffing, with more than 10,000 employees. With commitment and by listening to what people want, we help people and companies to find the solutions they need to develop. The Proffice share is listed on Nasdaq OMX Stockholm, Mid Cap. www.proffice.com.

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.

Proffice Aktiebolag may be required to disclose the information provided herein pursuant to the Securities Markets Act. The information was submitted for publication at 08.00 a.m. CET on 21 November, 2012.

This information was brought to you by Cision http://www.cisionwire.com